Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
Oncology On nuclear medicine and oncology, SHINE Technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
Events Partner Content 4th Targeted Radiopharmaceuticals Summit Europe Join the primary assembly of pioneering TRP developers
Partner Content Partner Content SpectronRx Receives U.S. Nuclear Regulatory Commission Mater... Leading Radiopharma CDMO Opens Second Location
News JPM: AbbVie pays $650m upfront for RemeGen cancer drug AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
